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Probiotic-Associated Aspiration Pneumonia Due to Lactobacillus
rhamnosus
Christopher D. Doern,a Sean T. Nguyen,b Folashade Afolabi,c Carey-Ann D. Burnhamd
Virginia Commonwealth University Health System, Department of Pathology, Richmond, Virginia, USAa; Children’s Medical Center, Department of Pharmacy, Dallas, Texas,
USAb; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USAc; Washington University School of Medicine, Department of
Pathology and Immunology and Department of Pediatrics, St. Louis, Missouri, USAd
Lactobacilli are low-virulence, commensal organisms of the gastrointestinal and genitourinary tracts and are commonly used as
“probiotic supplements.” Herein, we describe an episode of respiratory syncytial virus (RSV) bronchiolitis with bacterial super-
infection secondary to administration of Lactobacillus rhamnosus in an 11-month-old female with trisomy 21.
CASE REPORT
An 11-month-old female with trisomy 21 presented withvomiting and fever. The patient had a past medical history
significant for esophageal atresia, which was repaired 10
months earlier, subsequently requiring multiple balloon dila-
tions. The patient had dysphagia and was gastrostomy tube
(G-tube) dependent. Approximately 1 week prior to admis-
sion, the patient was admitted for an esophageal dilation and
developed hematemesis, which required intubation and admis-
sion to the pediatric intensive care unit (PICU). She was extu-
bated the next day and ultimately discharged home after 4 days
of hospitalization given the lack of evidence for esophageal
perforation on esophagram and clinical improvement. She had
been doing well until 1 day prior to admission, when she had an
episode of emesis and developed a fever to 101°F. In the emer-
gency department, a chest X ray was performed and interpreted
as concerning for a right-sided infiltrate versus atelectasis. The
patient was administered intravenous clindamycin and admit-
ted for presumed aspiration pneumonia. Overnight, the pa-
tient remained febrile and became hypoxic. A respiratory
pathogen panel (RPP) (BioFire; FilmArray, Salt Lake City, UT)
was performed and found to be positive for respiratory syncy-
tial virus (RSV), which subsequently led to a discontinuation of
clindamycin. The patient remained febrile for 3 days, and O2
saturations continued to be between 80 and 90%. A repeat
chest X ray demonstrated progression of pneumonia, demon-
strated by complete opacification secondary to her atelectasis
of the right lung. At that time, ceftriaxone was initiated, and a
pulmonary consult was sought. During this assessment, she
was diagnosed with RSV bronchiolitis and presumed bacterial
superinfection, which required an admission to the PICU for
further management of her hypoxia and increasing respiratory
distress. Following admission to the PICU, a broncheoalveolar
lavage (BAL) was performed, and the BAL fluid sample was
submitted to microbiology for RPP testing as well as bacterial
and fungal culture. The RPP was again positive for RSV, while
fungal cultures were negative. The BAL fluid specimen Gram
stain showed many white blood cells (WBC), rare ciliated re-
spiratory epithelial cells, rare alveolar macrophages, many red
blood cells (RBC), andmany Gram-positive rods. The bacterial
culture grew 100,000 CFU/ml of Gram-positive rods and
1,000 CFU/ml of mixed respiratory flora. The Gram-positive
rod grew both aerobically and anaerobically and was alpha-
hemolytic and catalase negative. The organism was identified
by matrix-assisted laser desorption ionization–time of flight
mass spectrometry (MALDI-TOF MS). Both the Biotyper ver-
sion 3.0 (Bruker Daltonics, Billerica, MA) and the Vitek MS
(IVD Knowledge Base v2.0) (bioMérieux, Marcy l’Etoile,
France) identified the organism as Lactobacillus rhamnosus. Us-
ing gradient diffusion testing performed on blood Mueller-Hin-
ton agar and incubated for 24 h (Etest; bioMérieux,Marcy l’Etoile,
France), the isolate was found to be susceptible to penicillin (MIC,
0.5 g/ml) but resistant to vancomycin (MIC, 256 g/ml) (1).
Given these findings, ceftriaxone was discontinued and intrave-
nous ampicillin-sulbactam was administered for 10 days. The pa-
tient gradually recovered over a 2-week period. Two endotracheal
tube aspirates were collected 1 and 15 days after initiation of am-
picillin-sulbactam, which were negative for the presence of Lacto-
bacillus by both direct Gram stain and culture.
During the course of this patient’s illness, it was discovered
that she had been taking the Lactobacillus rhamnosus-contain-
ing probiotic Culturelle (probiotic strain referred to as “LGG”)
(Culturelle, Cromwell, CT) for 3 months prior to her illness. A
capsule of the probiotic was obtained and cultured, and the
isolated organism was confirmed to be L. rhamnosus by
MALDI-TOFMS. Strain typing of the L. rhamnosus isolates was
performed using repetitive sequence PCR (REP-PCR) with the
primer RW3A as previously described (2, 3). PCR products
were resolved on the Agilent 2100 (Agilent, Santa Clara, CA),
and the relatedness of the strains was evaluated using Diversi-
lab software (bioMérieux, Durham, NC). The probiotic strain
and the patient’s strain were identical, with a similarity index of
99%. A control strain of Lactobacillus rhamnosus isolated by
the lab during the same time framewas also analyzed and found to
be unrelated to the index patient’s isolate (similarity index of
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70% to the index isolate) (Fig. 1). To our knowledge, this is the
first reported case of Lactobacillus pneumonia related to supple-
mentation with probiotics.
Discussion and review of the literature.We have described a
case of probiotic-associated pneumonia secondary to RSV infec-
tion in a patientwith trisomy 21 and a history of esophageal atresia
but whowas otherwise thought to be immunocompetent. Herein,
we provide both clinical and microbiological evidence that the
probiotic strain (LGG) was a cause of disease in this patient. Clin-
ically, the treating physicians had suspicion of bacterial superin-
fection based on the patient’s deteriorating respiratory status as
well as imaging studies. In addition, the patient was managed as
though she had a Lactobacillus infection, where empirical vanco-
mycin and ceftriaxone were switched to ampicillin-sulbactam in
response to isolation of Lactobacillus in culture. Laboratory evi-
dence was also consistent with an infection; the specimen’s Gram
stain demonstrated inflammatory cells as well as abundant Gram-
positive rods. The culture results supported this finding with
abundant and predominant growth of Lactobacillus rhamnosus
and strongly suggested a pathogenic role.
The mechanism by which the patient developed this infection
is not clear. We hypothesize that the patient aspirated the probi-
otic strain while being predisposed to serious bacterial infection as
a result of her ongoing RSV infection. Indeed, the patient would
later be diagnosed with a tracheoesophageal fistula, further sup-
porting this hypothesis. RSV-infected individuals are at risk for
secondary bacterial infection, and those with trisomy 21 are at
particular risk for severe RSV infection (4, 5). Despite the patient’s
risk factors, Lactobacillus pneumonia is very rare. A review of the
literature identified only 11 cases of Lactobacillus pneumonia (6–
14). The rarity of cases makes it difficult to draw conclusions
about risk factors for disease, but being immunocompromised
(especially having AIDs) appears to be the primary risk factor.
Lactobacilli are low-virulence organisms that are commensals
of the genitourinary and gastrointestinal tracts and are commonly
used as probiotic supplements (15). In the rare instances where
Lactobacillus causes disease, it is usually in the form of bacteremia
in patients who are either immunocompromised or have intrave-
nous catheters (16). This is the first published case of probiotic-
associated pneumonia. It is one of only 19 previous cases in which
the infecting Lactobacillus isolate was confirmed by strain typing
to be identical to the probiotic strain being taken by the patient
(17–23). Eighteen of these 19 cases were bloodstream infections,
with the 19th being a case of liver abscess. Interestingly, 5 of the 19
confirmed cases were pediatric patients, 3 of which had short gut
syndrome (22).
To date, a number of other studies have associated probiotic
use with infection. The majority of cases are bloodstream infec-
tions, but other disease manifestations, such as urinary tract in-
fection and peritonitis, have also been reported (24–28). Several
studies have looked at the safety of LGG probiotic use at the insti-
tutional level and found that its use is safe and does not lead to an
increase in infectious complications. Whelan and Meyers con-
ducted a literature review of randomized and nonrandomized tri-
als with the goal of investigating the safety of probiotic use (29).Of
the 72 articles that fulfilled their inclusion criteria, they found 20
case reports of adverse events in 32 patients. Of these, themajority
of infections were due to Saccharomyces boulardii, with only 5
identified cases resulting from LGG, all of which were blood-
stream infections. Honeycutt and colleagues conducted a ran-
domized placebo-controlled trial in which they asked whether
probiotic use could reduce the rates of nosocomial infection in a
pediatric intensive care unit (30). The numbers were small in this
study, and they were not able to show that LGG administration
reduced infection in this patient population. Importantly though,
they did not identify any LGG infections during the study. These
findings are contrary to those of Luong et al., who found an in-
crease LGG disease in their hospital immediately after the hospital
formulary switched from Lactobacillus acidophilus or Lactobacillus
helveticus to Lactobacillus rhamnosus (31).
In conclusion, we describe the first case of probiotic-associated
L. rhamnosus pneumonia. Our case is of particular interest be-
cause it occurred secondary to a respiratory viral infection. One of
the reported benefits of L. rhamnosus probiotic use is to help pre-
vent the development of severe respiratory tract infection, espe-
cially those due to respiratory viruses, including RSV (32–34).
These data provide an important example of how normal non-
pathogenic probiotic strains can cause real disease in vulnerable
patient populations. With that being said, it is important to point
out that while probiotics are frequently consumed, there is an
extremely low incidence of infection due to these strains. The pur-
pose of this report is to serve as an example of how extenuating
circumstances can render a patient susceptible to probiotic infec-
tion.
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